Blood Glucose Monitoring System Market Trend, Share, Growth, Size and Forecast 2030

Blood Glucose Monitoring System Market

Blood Glucose Monitoring System Market Size, Share, Growth, Forecast to 2028

Category: Medical Device Report Format : PDF Pages: 205 Report Code: ZMR-3435 Published Date: Jun-2022 Status : Published

Blood Glucose Monitoring System Market

Table Of Content

Methodology

Free Analysis

Blood glucose monitoring devices are used to detect the glucose level in the blood. Glucose is a type of sugar present at a certain level in a human body. When this glucose level drops, a person suffers from diabetes. Blood glucose monitoring devices are used to monitor the glucose levels of diabetic patients.

The occurrence of diabetes is increasing at an exponential pace worldwide and has become one of the serious health concerns. WHO (World Health Organization) declared it a global epidemic due to its rapidly increasing prevalence. Approximately 30.3 million, i.e., 9.4% of the U.S. population is suffering from diabetes. The global incidence of diabetes has risen from 4.7% to 8.5%, i.e., doubled since the 1980s in adults. Increased prevalence of diabetes is mainly driving the growth of the blood glucose monitoring system market. Additionally, the increase in adoption of sugar surveillance system, increase in adoption of minimally invasive techniques, growing the aging population, technological advancements in the blood glucose monitoring systems, and rising awareness about the use of these systems in developing regions is anticipated to fuel the growth of the global blood glucose monitoring system market.  

Global Blood Glucose Monitoring System Market

The blood glucose monitoring system market is segmented on the basis of product type, testing site, indication, and end-user. Based on product type, the market for the blood glucose monitoring system is further segmented into self-monitoring devices and continuous glucose monitoring devices. Self-monitoring devices segment is further sub-segmented into blood glucose meters, lancets & lancets devices, and testing strips. The self-monitoring devices segment is dominating the global market for blood glucose monitoring system, owing to the rapid product development. On the basis of testing site, this market is further segmented into fingertip testing and alternate testing site. Fingertip testing is anticipated to dominate the market due to its accuracy. Based on the indication, the blood glucose monitoring system market is segmented into type-I diabetes, type-II diabetes, and gestational diabetes. Type-I and type-II diabetes are further sub-segmented into adult and pediatrics. Type-II diabetes segment is anticipated to dominate the application segment of blood glucose monitoring devices, due to the increase in the prevalence of this diabetes type. The end-user segment includes hospitals, clinics, and homecare. Homecare segment is anticipated to dominate the market.

North America is anticipated to dominate the market in the forecast period, due to rise in the initiatives undertaken by the government for prevention and treatment of diabetes with the help of leading players of the region, the rapid use of well-developed technology, and increase in R&D activities. The Asia Pacific is expected to show the highest growth due to an increase in the population suffering from diabetes. The increase in the aging population, lifestyle-associated changes, rising awareness regarding diabetes, and rapid urbanization are some of the factors fueling the growth of the blood glucose monitoring system market in the Asia Pacific region.

The key players operating in the global blood glucose monitoring system market are Abbott Laboratories, Novo Nordisk A/S, Hoffmann-La Roche Ltd., Sanofi, Medtronic, Nova Biomedical, B. Braun Melsungen, Terumo Corporation, ARKRAY Inc., and Becton, Dickinson, and Company. These companies focus on developing new technologies and getting it FDA approved so that they can launch it. For instance, in 2018, Medtronic received approval from FDA for smart continuous glucose monitor. In 2017, Abbott received approval from FDA for the first continuous glucose monitoring system that does not require blood sample calibration.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

twitter

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed